Karl R Aigner
Overview
Explore the profile of Karl R Aigner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
29
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Magyar C, Rai A, Aigner K, Jamadar P, Tsui T, Gloor B, et al.
Langenbecks Arch Surg
. 2023 Feb;
408(1):78.
PMID: 36745231
Purpose: Gastric cancer (GC) is the fifth most common malignancy worldwide and portends a grim prognosis due to a lack of appreciable improvement in 5-year survival. We aimed to analyze...
2.
Vashist Y, Aigner K, Gailhofer S, Aigner K
Cancers (Basel)
. 2022 Aug;
14(15).
PMID: 35954364
Background: Current therapeutic options in diffuse metastatic cholangiocarcinoma (CCC) are limited with unsatisfactory results. We evaluated the efficacy of regional chemotherapy (RegCTx) using arterial infusion (AI), hypoxic stop-flow abdominal perfusion...
3.
Vashist Y, Aigner K, Dam M, Gailhofer S, Aigner K
Curr Oncol
. 2022 Jul;
29(7):4868-4878.
PMID: 35877246
Background: Therapeutic options in metastatic esophageal cancer (EC) are limited with unsatisfactory results. We evaluated the efficacy of regional chemotherapy (RegCTx) approach in diffuse metastatic EC using arterial infusion (AI),...
4.
Aigner K, Gailhofer S, Aigner K
Mol Clin Oncol
. 2021 May;
14(6):129.
PMID: 33981433
To overcome drug resistance in relapsed ovarian cancer, an isolated perfusion system was used to generate a higher local exposure to cytostatic drugs. In addition to cisplatin as the cytostatic...
5.
Aigner K, Lavinski Y, Gailhofer S
Int J Surg Case Rep
. 2021 Jan;
77:816-821.
PMID: 33395903
Introduction: We present a case series of three patients with advanced cervical cancer who either refused the standard of care systemic or chemoradiation treatment or did not benefit from it....
6.
Aigner K, Selak E, Aigner K
Int J Surg Case Rep
. 2020 Sep;
75:71-74.
PMID: 32919332
Introduction: This is a report about the first case of an advanced stage IV tonsil carcinoma treated with isolated thoracic perfusion and chemofiltration. Presentation Of Case: The tumor extended beyond...
7.
Aigner K, Gailhofer S, Selak E, Aigner K
J Cancer Res Clin Oncol
. 2019 Sep;
145(11):2855-2862.
PMID: 31506738
Purpose: The treatment of pancreatic carcinoma remains a challenge as prognosis is poor, even if confined to a single anatomical region. A regional treatment of pancreatic cancer with high drug...
8.
Aigner K, Selak E, Aigner K
J Cancer Res Clin Oncol
. 2018 Nov;
145(1):261-268.
PMID: 30382368
Purpose: Head and neck cancer treatment achieves good locoregional tumor control rates while causing severe side effects. Therapy with chemotherapeutic drugs administered intravenously is limited because either the concentrations at...
9.
Aigner K, Gailhofer S
Anticancer Res
. 2005 Dec;
25(6C):4407-12.
PMID: 16334117
Background: Despite various chemotherapeutic drugs and combinations given systemically, the impact of these agents on survival has not been convincing, and drug-related toxicity continues to be the limiting factor. Patients...